Apotex Ferriprox NDA Will Seek First-Line Claim; Fall Submission Planned
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Apotex’ upcoming NDA for the iron-chelating agent Ferriprox will seek a first-line indication for treatment of iron overload in thalassemia patients.
You may also be interested in...
Ferraprox Advisory Cmte: Can Risk Management Overcome Safety, Dosing Worries?
ApoPharma's transfusional iron overload treatment has been approved in Europe since 1999, but FDA sent a "complete response" letter in 2009.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product